Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease

Kidney International

Volumn 73, Issue 1, 2008, Pages 95-101

  Ravani, P ^a   Tripepi, G ^b   Pecchini, P ^a   Mallamaci, F ^b   Malberti, F ^a   Zoccali, C ^b,c  

^a CREMONA HOSPITAL   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

^c BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

Chronic kidney disease; End stage renal disease; Epidemiology and outcome; Renal failure; Risk factor; Urotensin II

Indexed keywords

SERUM ALBUMIN; UROTENSIN II;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENTAL FINDING; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RISK FACTOR;

EID: 37249064837     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002565     Document Type: Article

References (35)

1. Ames RS, Sarau HM, Chambers JK et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999; 401: 282-286.
2. Affolter J, Webb DJ. Urotensin II: a new mediator in cardiopulmonary regulation? Lancet 2001; 358: 774-775.
3. Richards AM, Charles C. Urotensin II in the cardiovascular system. Peptides 2004; 25: 1795-1802.
4. Cheung BM, Leung R, Man YB et al. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004; 22: 1341-1344.
5. Hassan GS, Douglas SA, Ohlstein EH et al. Expression of urotensin-II in human coronary atherosclerosis. Peptides 2005; 26: 2464-2472.
6. Richards AM, Nicholls MG, Lainchbury JG et al. Plasma urotensin II in heart failure. Lancet 2002; 360: 545-546.
7. Douglas SA, Tayara L, Ohlstein EH et al. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002; 359: 1990-1997.
8. Langham RG, Kelly DJ, Gow RM et al. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 2004; 44: 826-831.
9. Wassef L, Langham RG, Kelly DJ. Vasoactive renal factors and the progression of diabetic nephropathy. Curr Pharm Des 2004; 10: 3373-3384.
10. Totsune K, Takahashi K, Arihara Z et al. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 2003; 104: 1-5.
11. Zoccali C, Mallamaci F, Tripepi G et al. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. Kidney Int 2006; 69: 1253-1258.
12. Totsune K, Takahashi K, Arihara Z et al. Role of urotensin II in patients on dialysis. Lancet 2001; 358: 810-811.
13. Stirrat A, Gallagher M, Douglas SA et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001; 280: H925-H928.
14. Affolter JT, Newby DE, Wilkinson IB et al. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 2002; 54: 617-621.
15. Bohm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002; 135: 25-27.
16. Sondermeijer B, Kompa A, Komesaroff P et al. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 2005; 18: 1195-1199.
17. Lim M, Honisett S, Sparkes CD et al. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 2004; 109: 1212-1214.
18. Mallamaci F, Cutrupi S, Pizzini P et al. Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. J Nephrol 2005; 18: 727-732.
19. Gruson D, Rousseau MF, Ahn SA et al. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 2006; 27: 1527-1531.
20. Joyal D, Huynh T, Aiyar N et al. Urotensin-II levels in acute coronary syndromes. Int J Cardiol 2006; 108: 31-35.
21. Khan SQ, Bhandari SS, Quinn P et al. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 2007; 117: 323-328.
22. Matsushita M, Shichiri M, Imai T et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001; 19: 2185-2190.
23. Shenouda A, Douglas SA, Ohlstein EH et al. Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma. J Histochem Cytochem 2002; 50: 885-889.
24. Song W, bdel-Razik AE, Lu W et al. Urotensin II and renal function in the rat. Kidney Int 2006; 69: 1360-1368.
25. Charles CJ, Rademaker MT, Richards AM et al. Urotensin II: evidence for cardiac, hepatic and renal production. Peptides 2005; 26: 2211-2214.
26. Balat A, Pakir IH, Gok F et al. Urotensin-II levels in children with minimal change nephrotic syndrome. Pediatr Nephrol 2005; 20: 42-45.
27. Totsune K, Takahashi K, Arihara Z et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 2004; 25: 1809-1814.
28. Mallamaci F, Cutrupi S, Pizzini P et al. Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens 2006; 19: 505-510.
29. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
30. Sims RJ, Cassidy MJ, Masud T. The increasing number of older patients with renal disease. BMJ 2003; 327: 463-464.
31. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808.
32. Bottrill FE, Douglas SA, Hiley CR et al. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 2000; 130: 1865-1870.
33. Sidharta PN, Wagner FD, Bohnemeier H et al. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 2006; 80: 246-256.
34. Levey AS, Greene T, Kusek J et al. A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]. J Am Soc Nephrol 2000; 11: A0828.
35. Hosmer DW, Lemeshow S. Assessment of Model Adequacy. Applied Survival Analysis, 196-240. Wiley & sons: New York, 1999.